<?xml version="1.0" encoding="UTF-8"?>
<fig id="ijms-18-02645-f001" orientation="portrait" position="float" class="fig">
 <label class="label">Figure 1</label>
 <caption class="caption">
  <p class="p">Omega-3 polyunsaturated fatty acid (PUFA) potential action in restoring eubiosis in gut microbiota. Dysbiosis of the 
   <italic class="italic">Firmicutes/Bacteroidetes</italic> ratio is associated with several conditions, such as weight gain and obesity [
   <xref rid="B56-ijms-18-02645" ref-type="bibr" class="xref">56</xref>], insulin resistance [
   <xref rid="B56-ijms-18-02645" ref-type="bibr" class="xref">56</xref>], high-fat diet [
   <xref rid="B38-ijms-18-02645" ref-type="bibr" class="xref">38</xref>,
   <xref rid="B39-ijms-18-02645" ref-type="bibr" class="xref">39</xref>], gut permeability [
   <xref rid="B54-ijms-18-02645" ref-type="bibr" class="xref">54</xref>], IBDs [
   <xref rid="B21-ijms-18-02645" ref-type="bibr" class="xref">21</xref>], and depression [
   <xref rid="B88-ijms-18-02645" ref-type="bibr" class="xref">88</xref>]. Similarly, a 
   <italic class="italic">Bifidobacteria</italic> decrease combined with a 
   <italic class="italic">Enterobacteria</italic> increase leads to the establishment of endotoxemia that causes a chronic low-grade inflammation associated with some pathological conditions, like insulin resistance [
   <xref rid="B46-ijms-18-02645" ref-type="bibr" class="xref">46</xref>], gut permeability [
   <xref rid="B43-ijms-18-02645" ref-type="bibr" class="xref">43</xref>,
   <xref rid="B44-ijms-18-02645" ref-type="bibr" class="xref">44</xref>], and depression [
   <xref rid="B92-ijms-18-02645" ref-type="bibr" class="xref">92</xref>]. Initial evidence shows that omega-3 PUFAs are able to reverse this condition by restoring the 
   <italic class="italic">Firmicutes/Bacteroidetes</italic> ratio, and increasing 
   <italic class="italic">Lachnospiraceae</italic> taxa [
   <xref rid="B13-ijms-18-02645" ref-type="bibr" class="xref">13</xref>,
   <xref rid="B16-ijms-18-02645" ref-type="bibr" class="xref">16</xref>,
   <xref rid="B18-ijms-18-02645" ref-type="bibr" class="xref">18</xref>,
   <xref rid="B19-ijms-18-02645" ref-type="bibr" class="xref">19</xref>,
   <xref rid="B20-ijms-18-02645" ref-type="bibr" class="xref">20</xref>], both associated with an increased production of the anti-inflammatory short-chain fatty acid (SCFA) butyrate [
   <xref rid="B13-ijms-18-02645" ref-type="bibr" class="xref">13</xref>,
   <xref rid="B19-ijms-18-02645" ref-type="bibr" class="xref">19</xref>,
   <xref rid="B20-ijms-18-02645" ref-type="bibr" class="xref">20</xref>]. Moreover, animal studies showed the ability of omega-3 PUFAs to increase lipopolysaccharide (LPS)-suppressing bacteria, 
   <italic class="italic">Bifidobacteria</italic>, and to decrease LPS-producing bacteria, 
   <italic class="italic">Enterobacteria</italic>, negating the endotoxemia phenomenon [
   <xref rid="B52-ijms-18-02645" ref-type="bibr" class="xref">52</xref>]. For all these actions, omega-3 PUFAs can be considered as prebiotics, able to restore gut eubiosis in some pathological conditions.
  </p>
 </caption>
 <graphic xlink:href="ijms-18-02645-g001" class="graphic" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</fig>
